

Title (en)

METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF MACULAR DEGENERATION

Title (de)

VERFAHREN ZUR VERWENDUNG VON UNUZUSAMMENSETZUNGEN MIT SELEKTIVEN ZYTOKIN-HEMMERN ZUR BEHANDLUNG UNVERSORGUNG VON MAKULADEGENERATION

Title (fr)

METHODES D'UTILISATION ET COMPOSITIONS CONTENANT DES SUBSTANCES MEDICAMENTEUSES D'INHIBITION SELECTIVE DES CYTOKINES POUR TRAITER ET CONTROLER LA DEGENERESCENCE

Publication

EP 1567148 A4 20100915 (EN)

Application

EP 03779423 A 20031031

Priority

- US 0334535 W 20031031
- US 42290002 P 20021031

Abstract (en)

[origin: WO2004041181A2] Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

IPC 1-7

A61K 31/40; **A61K 31/00**; **A61K 31/4035**; **A61P 27/02**

IPC 8 full level

A61K 31/454 (2006.01); **A61K 31/522** (2006.01); **A61K 31/545** (2006.01); **A61K 31/557** (2006.01); **A61K 31/56** (2006.01); **A61K 38/18** (2006.01); **A61K 38/21** (2006.01); **A61K 38/27** (2006.01)

CPC (source: EP KR)

A61K 31/40 (2013.01 - KR); **A61K 31/404** (2013.01 - KR); **A61K 31/454** (2013.01 - EP); **A61K 31/522** (2013.01 - EP); **A61K 31/545** (2013.01 - EP); **A61K 31/557** (2013.01 - EP); **A61K 31/56** (2013.01 - EP); **A61K 38/185** (2013.01 - EP); **A61K 38/21** (2013.01 - EP); **A61K 38/27** (2013.01 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 27/02** (2017.12 - EP)

C-Set (source: EP)

1. **A61K 38/185** + **A61K 2300/00**
2. **A61K 38/21** + **A61K 2300/00**
3. **A61K 38/27** + **A61K 2300/00**

Citation (search report)

- [XP] WO 03088972 A1 20031030 - SMITHKLINE BEECHAM CORP [US], et al
- [E] WO 03097040 A1 20031127 - CELGENE CORP [US], et al
- [E] WO 2004034962 A2 20040429 - CELGENE CORP [US], et al
- [A] WO 0134606 A1 20010517 - CELGENE CORP [US], et al
- [X] DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1999, VEROUGSTRAETE C: "[Present and future treatment of age-related macular degeneration]", XP002590511, Database accession no. NLM10546384
- [X] DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; May 2002 (2002-05-01), HATTENBACH LARS-OLOF ET AL: "Detection of inducible nitric oxide synthase and vascular endothelial growth factor in choroidal neovascular membranes.", XP002590512, Database accession no. NLM12065859
- [XP] MILLER D W ET AL.: "[The molecular mechanisms of neovascular age-related macular degeneration]", DER OPHTHALMOLOGE : ZEITSCHRIFT DER DEUTSCHEN OPHTHALMOLOGISCHEN GESELLSCHAFT FEB 2003 LNKD- PUBMED:12589451, vol. 100, no. 2, February 2003 (2003-02-01), pages 92 - 96, XP002590513, ISSN: 0941-293X
- [AP] RADU ROXANA A ET AL: "Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 15 APR 2003 LNKD- PUBMED:12671074, vol. 100, no. 8, 15 April 2003 (2003-04-15), pages 4742 - 4747, XP002590514, ISSN: 0027-8424
- [A] FEKRAT S ET AL: "THE EFFECT OF ORAL 13-CIS-RETINOIC ACID ON RETINAL REDETACHMENT AFTER SURGICAL REPAIR IN EYES WITH PROLIFERATIVE VITREORETINOPATHY", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 102, no. 3, 1 March 1995 (1995-03-01), pages 412 - 418, XP000942676, ISSN: 0161-6420 & BULLETIN DE LA SOCIÉTÉ BELGE D'OPHTALMOLOGIE 1999 LNKD- PUBMED:10546384, vol. 273, 1999, pages 79 - 101, ISSN: 0081-0746
- See references of WO 2004041181A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2004041181 A2 20040521; **WO 2004041181 A3 20050217**; AU 2003285107 A1 20040607; AU 2003285107 B2 20080110; BR 0315889 A 20051004; CA 2504263 A1 20040521; CN 1731997 A 20060208; EP 1567148 A2 20050831; EP 1567148 A4 20100915; JP 2006509743 A 20060323; KR 20050062649 A 20050623; MX PA05004486 A 20050726; NZ 540185 A 20080131; TW 200418455 A 20041001; ZA 200503468 B 20061025

DOCDB simple family (application)

US 0334535 W 20031031; AU 2003285107 A 20031031; BR 0315889 A 20031031; CA 2504263 A 20031031; CN 200380108090 A 20031031; EP 03779423 A 20031031; JP 2004550274 A 20031031; KR 20057007608 A 20050429; MX PA05004486 A 20031031; NZ 54018503 A 20031031; TW 92130486 A 20031031; ZA 200503468 A 20031031